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POROUS MICROSPHERES FOR DRUG 
DELIVERY AND METHODS FOR MAKING SAME 
This application is a continuation of application Ser. 
No. 551,414, ?led Nov. 14, 1983, and now abandoned. 
BACKGROUND OF THE INVENTION 
(1) Field of the Invention 
The present invention relates generally to spherical 
polymer matrices for the controlled release of various 
drug(s) or other selected agents. More particularly, this 
invention describes methodology for preparing highly 
porous spherical polymer matrices with preselected 
incorporated agents, e.g., therapeutics, dispersed within 
the con?nes of the pores therein for controlled delivery 
to target physiological systems and resulting biodegrad 
able microspheric drug carrier or controlled delivery 
systems. 
(2) State of the Art 
A wide variety of microencapsulation drug delivery 
systems have been developed heretofore for the rate 
controlled release of therapeutics or other agents. For 
instance, considerable research has been devoted to 
incorporating therapeutic agents into polyesters such as 
polye-caprolactone), poly(e-capro1actone-CO-DL-lac 
tic acid), poly(DL-lactic acid), poly(DL~lactic acid 
CO-glycolic acid) and polye-caprolactone-CO-glycolic 
acid) in which release was diffusion controlled. See, for 
example, Pitt, C. G. (Pitt, C. G., Gratzl, M. M., Jeffcoat, 
A. R., Zweidinger, R., Schindler, A., Sustained Drug 
Delivery Systems. II. Factors Affecting Release Rates 
from Poly(e-caprolactone) and Related Biodegradable 
Polyesters. J. Pharm. Sci, 68, 1534 (1979). These sys 
tems were fabricated as ?lms and capsules and the re 
sults suggest that the devices can be prepared to erode 
after release of the drug is essentially completed. Degra 
dation of at least the polyesters has been reported to 
proceed by random hydrolytic cleavage of ester link 
ages by an autocatalytic process the rate of chain cleav 
age being in?uenced by chemical and morphological 
factors. 
Sustained release systems of antimalarial agents and 
sulfadiazine in glycolic-lactic acid copolymers have also 
been reported. Wise, D. L., Gesser, J. D., McCormick, 
G. J., Sustained Release of a Dual Anti-malarial System, 
J. Pharm. Pharmacol., 31, 201 (1979). Wise, D. L., Mc 
Cormick, G. J., Willet, G. R, Anderson, L. C., Sus 
tained Release of an Antimalarial Drug Using a Copoly 
mer of Glucolic/Lactic Acid, Life Sci., 19, 867 (1976). 
Wise, D. L. , McCormick, G. J., Willet, G. P., Ander 
son, L. C., Howes, J. F., J. Pharm. PharmacoL, 30, 686 
(1978). Methods reported by the foregoing investigators 
involved dissolving the agents in a suitable solvent and 
either spray drying or casting ?lms according to usual 
methods and evaporating the solvent. Various narcotic 
antagonists and steroids have been incorporated in ?lms 
and implanted in rats [e.g., see Woodland, J. H. R., 
Yolles, 8., Blake, D. A., Helrich, M., Meyer, F.J., 
Long-Acting Delivery Systems for Narcotic An 
tagonists:I. .l Med. Chem, 16, 897 (1973). .Iackanicz, T. 
M., Nash, H. A., Wise, D. L., Gregory, J. B., Polylactic 
Acid as a Biodegradable Carrier for Contraceptive 
Steroids, Contraception, 8, 22.7 (1973). Anderson, L. C., 
Wise, D. L., Howes, J. F., An Injectable Sustained 
Release Fertility Control System, Contraception, 13, 375 
(1976)] and incorporated into particles injected subcuta 
neously [Yo1les, S., Time-Release Depot for Anticancer 
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Drugs: Release of Drugs Covalently Bonded to Poly 
mers, J. Parent, DrugAssoa, 32, 188 (1978)]. The release 
of a number of anti~tumor agents has been evaluated in 
implantable systems as reported in lYolles, 5., Time 
Release Depot for Anticancer Drugs: Release of Drugs 
Covalently Bonded to Polymers, J. Parent, Drug Assoc, 
32, 188 (1978)], and the antibiotic Mitomycin C has been 
encapsulated in microspherical carriers of gelatin and 
administered intraveneously [Y oshioka, T., Hashida, 
M., Muranishi, S., and Sezaki, H., Speci?c Delivery of 
Mitomycin C to Liver, Spleen and Lung: Nano-and 
Microspherical Carriers of Gelatin. Intern J. Pharm, 81, 
131 (1981)]and the effect of size on in vivo distribution 
and the potential for antibiotic targeting discussed. The 
size distribution of the microspheres (i.e. 5-30 pm) re 
ported in the last mentioned publication was very 
broad, especially for intravenous administration. Re 
cently the in-vitro release of local anesthetics from 
polylactic acid spheres prepared by a solvent evapora 
tion process has, likewise, been reported [Wakiyama, 
N., Kaxuhiko, J., Nakano, M., In?uence of Physico 
chemical Properties of Polylactic Acid on'the Charac 
teristics and In Vitro Release Patterns of Polylactic 
Acid Microspheres Containing Local Anesthetics, 
Chem. Pharm. BulL, 30, 2621 (1982)]. The patterns of 
release from these polylactic acid spheres were charac 
terized by the various degrees of degradation of the 
polymer as well as solubilities of loaded drugs although 
no attempt was apparently made to evaluate this param 
eter. Additionally, it is apparent that the solubility of the 
drug played an important role in the rate and extent of 
release. Scanning electron photomicrographs also re 
vealed varying degrees of erosion and deformation of 
the spheres after release. 
It will be seen from the foregoing that while the 
controlled release delivery of pharmaceuticals or other 
agents from heretofore described polymeric systems has 
been principally limited to oral, topical or implantable 
systems in which the considerations relative to pore size 
and/or cell size within the carrier matrix as well as the 
overall dimensions of the microspheres to be adminis 
tered along with the rate of release and the relative 
absorption rate from a bioavailability standpoint are 
distinctly different from the evaluation parameters in 
volved in the utilization of these microsphere delivery 
systems for parenteral, i.e., intravenous, intraarterial, 
intraocular or inhalation administration routes to which 
the present invention is particularly applicable. 
SUMMARY OF THE INVENTION 
It is, therefore, a primary object of the present inven 
tion to afford novel porous microspheres for the con 
trolled delivery of drugs or other matrix con?ned mate 
rials to target organs or systems in warm-blooded ani 
mals in need thereof and to methods for making such 
microspheres. 
A further object of the present invention is to provide 
methods for preparing porous microspheres of hereto 
fore unattainable narrow-range size distribution particu 
larly suitable for use as parenterally administerable drug 
delivery systems for injectable and inhalation dosage 
forms as well as facilitating sustained drug release via 
more conventional oral administration routes. 
It is a still further object of the present invention to 
provide porous microsphere matrices wherein the ac 
cessability of the drug or other incorporated agent is not 
dependent upon the physical or chemical erosion of the 
polymer for release. 
4,818,542 
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Another object of the present invention is to provide 
chemically modi?ed polymer compositions suitable for 
use in the spherical polymer matrices of the invention 
whereby porosity as well as degradation of the polymer 
substrate after release of the matrix con?ned agent for 
release can be predetermined and controlled. 
A still further object of the present invention is to 
provide porous polymeric microspheric drug delivery 
systems which allow targeting of drugs or other agents 
to speci?c host tissues or cells via injection or inhalation 
providing high localized concentrations, sustained ac 
tivity, systemic administration and treatment not possi 
ble by other methods thereby minimizing undesirable 
systemic effects of toxic drugs administered directly 
into the circulation. 
These and other similar objects, advantages and fea 
tures are accomplished according to the methods, prod 
ucts and compositions of the present invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 is a drawing of a polymer with a low degree 
of crystallinity in accordance with the practice of the 
‘present invention and a drawing of a polymer with a 
high degree of crystallinity. 
FIG. 2 is a graph of half-life in months versus various 
ratios of polyglycolic (PGA) and polylactic (PLA) as 
copolymer implanted in rat tissues. 
FIG. 3 is graph of percent water uptake versus per 
cent glycolic acid for glycolide/lactide copolymers. 
FIGS. 4A and 4B generally depict the preparative 
methods of the present invention. 
FIGS. 5A and 5B depicts the shape and surface ap 
pearance of polyglycolic (PGA) microspheres prepared 
by Dilution-Prescriptation Method. 
FIGS. 6A and 6B depicts the shape and surface ap 
pearance of PGA microspheres prepared by Freeze 
Dry Method. 
FIG. 7 is a graph of the release pro?le from matrices 
which were prepared by Precipitation Method and 
contain different amounts of marker. 
FIG. 8 is a graph of the release pro?le form matrices 
which were prepared by Freeze Dry Method and con 
tain different amounts of marker. 
FIG. 9 is a graph of the release pro?le from matrices 
which were prepared by Freeze Dry Method and con 
tain prednisolone acetate. 
FIG. 10 depicts scanning electron micrography 
(SEM) micrographs of the PGA matrix manufactured 
by Freeze Dry Method 72 hours following drug release. 
FIG. 11 depicts SEM micrographs of the PGA ma 
trix manufactured by Freeze Dry Method after 120 
hours following drug release. 
FIG. 12 depicts SEM micrographs of the PGA ma 
trix manufactured by Freeze _Dry Method 168 hours 
following drug release. 
FIG. 13 is a graph of the release of dye from polymer 
in plasma. 
FIGS. 14A and 14B depict PGL microspheres con 
taining blue dye manufactured by Dilution-Prescipita 
tion Method. 
FIGS. 15A and 15B depict gelatin microspheres man 
ufactured by a modi?ed Dilution-Precipitation Method. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The porous polymeric microspheres of the present 
invention are derived from copolymeric and homopo 
lymeric polyesters containing hydrolyzable ester link 
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ages which are, therefore, bidoegradable. Typically 
preferred of such polyesters are polyglycolic (PGA) 
and polylactic (PLA) acids, and copolymers of glyco 
lide and L(-lactide) (PGL). The aforementioned polyes 
ters are particularly suited for the methods and compo 
sitions of the present invention by reason of their char~ 
acteristically low human toxicity and virtually com 
plete biodegradability. Of course, it will be understood 
that the particular polyester or other polymer, oligo 
mer, copolymer, etc., utilized as the microspheric poly— 
mer matrix is not critical and a variety of polymers may 
be utilized as a consequence of the novel processing 
methods of the invention which yield the desired micro 
spheres of the porosity, consistency, shape and size 
distribution essentially irrespective of the source 'of 
polymer utilized. Accordingly, other biodegradable or 
bioerodable polymers or copolymers evidencing the 
necessary low degree of toxicity suitable for use in the 
present invention include, for example, gelatin, agar, 
starch, arabinogalactan, albumin, collagen, natural and 
synthetic materials or polymers, such as, poly(e 
caprolactone), poly(e-caprolactone-CO-lactic acid), 
poly(e-caprolactone-CO-glycolic acid), poly(B 
hydroxy butyric acid), polyethylene oxide, polyethyl~ 
ene, poly(alkyl-Z-cyanoacrylate), (e.g., methyl, ethyl, 
butyl, etc.), hydrogels such as poly(hydroxyethyl meth 
acrylate), polyamides (e.g., polyacrylamide), 
poly(amino acids) (i.e., L-leucine, L-aspartic acid, B 
methyl-L-aspartate, B-benzyl-L-aspartate, glutamic 
acid and the like), poly(Z-hydroxyethyl DL-asparta 
mide), poly(ester urea), poly(L-phenylalanine/ ethylene 
glycol/1,6-diisocyanatohexane) and poly(methyl meth 
acrylate). 
The foregoing exemplary natural and synthetic poly 
mers suitable for use in the present invention are, of 
course, either readily available commercially or are 
obtainable by condensation polymerization reactions 
from the suitable monomers or, comonomers or oligo 
mers. For instance, homopolymers and copolymers of 
glycolic and lactic acids can be prepared by direct poly 
condensation or by reacting glycolide and lactide mon 
omers as disclosed by Gilding, D. K., Reed, A. M., 
Biodegradable Polymers for Use in Surgery - Poly 
glycolic/Poly?actic acid) Homo~ and Copolymers: 1, 
Polymer, 20, 1459 (1979). Structurally, polyglycolic 
acid (PGA) has the following structure: 
H o H o 
I II I ll 
II 
whereas the related copolymer polyglycolic acid/ 
polylactic acid (PGI; has the structure depicted below: 
II 
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-continued 
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II 
Both of the foregoing are polyester type polymers 
which readily degrade via hydrolysis at the ester link 
ages and by appropriately selecting suitable molecular 
weight polyesters, modifying the degree of cross-link 
ing and the degree of crystallinity, the biodegradation 
properties of such polymers may be advantageously 
controlled. As pointed out previously, however, in 
accordance with the present invention the necessity for 
biodegradation or bioerosion of the polymer matrix for 
release of the agent incorporated therein to occur is 
obviated by reason of the intrinsic porosity characteris 
tics of the polymer matrices of the invention and the 
fact that the incorporated agent or agents are matrix 
con?ned within the interconnecting channels or pores 
of the spherical polymer. However, in accordance with 
alternative and preferred embodiments of the present 
invention the possibility that the matrix could be coated 
with a ?lm or cross-linking agent to inhibit or control 
release, thereby allowing bioerosion to in?uence release 
is not in any way precluded and may, in fact, depending 
upon the nature of the incorporated agent as well as the 
rate of release required in the target organ system may 
be desirable or advantageous. For example, in those 
instances where it may be desirable to inhibit or retard 
drug release rates, more extensive cross-linking of the 
copolymer or polymer may be achieved by the addition 
of higher concentrations of suitable cross-linking agents 
such as glyoxal, succinaldehyde, glutaraldehyde, 3 
methylglutaraldehyde, methyleneacrylamide, bisacryl 
amide and similar cross-linking agents. Likewise, the 
reduction or elimination of crosslinks in the copolymers 
or polymers of the invention will result in enhanced 
biodegradability. On the basis of such polymer modi? 
cations, it is evident that the release of the incorporated 
agent or agents will be essentially complete, i.e., 90% 
before any erosion or degradation of the polymer ma 
trix occurs, and, thus, the polymer composition can be 
preselected to permit controlled clearance from the 
target system after release of the incorporated drug. 
The polymers utilized in accordance with the inven 
tion exist in the crystalline form with amorphous re 
gions interdispersed between the crystalline areas as 
shown, for example, in FIG. 1. Hydrolysis rates have 
been shown to be higher in the amorphous regions. For 
the copolymers of PLA/PGA, the degree of crystallin 
ity is reduced at a composition of equal amounts of PLA 
and PGA. As shown in FIG. 2, the half-life for the 
degradation of polymer in rat tissue was lowest at a 
50-50 composition. FIG. 3 shows that the water uptake 
is highest in this range which constitutes the amorphous 
region. Therefore bioerosion occurs in the amorphous 
regions initially and eventually the backbone is de 
stroyed and the matrix will collapse, thereby accelerat 
ing the bioerosion and elimination of the polymer. 
Consistent with the controlled conditions of the 
methods of the present invention, spherical polymer 
matrices or microspheres having a diameter range be 
tween about 1 to 150 microns (um) can be prepared in 
narrow size ranges for targeting to various organ or 
organ systems via parenteral injection or inhalation. A 
more preferred range for the spherical polymer matri 
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ces of microspheres is between about 0.5 to 50 microns. 
The integratable methods for preparing porous spheri 
cal matrices consistent with the present invention result 
in microspheres in which essentially all of the agent(s) 
incorporated within the pores of the drug delivery sys 
tem is readily available for release. Essentially the fore 
going principle objective of the invention is accom 
plished by forming emulsi?ed droplets or spheres con 
sisting of a homogeneous mixture of polymer (or 00 
polymer), solvent and matrix incorporated agent from a 
solution of a preselected polymer and agent dispersed in 
a continuous (non-solvent phase). Removal of the sol 
vent from the sphere by any one or combination of (1) 
freeze drying, or (2) dilution-precipitation extraction, 
creates the interconnecting network of pores wherein 
the incorporated agent is con?ned within the walls and 
channels of the pores as opposed to random distribution 
within the more poorly de?ned interstices of the poly 
mer. As used in the speci?cation and claims, the expres 
sion "pore incorporated agen ” is used to de?ne the 
relative speci?c location of the agent con?ned essen 
tially completely inside the pores of the porous micro 
spheres of the invention. Similarly, the term “agent” 
speci?cally encompasses any diagnostic or pharmaco 
logically active material which would be generally 
classi?able as a drug suitable for introduction into a 
human or other warmblooded animal host, as well as 
other materials or compositions including, for instance, 
dyes, antigens, antibodies, enzymes, ?avors, comestibles 
and the like and mixtures thereof. 
The drug delivery systems in accordance with the 
present invention are ideally suited for administration 
by parenteral or inhalation routes. It will be appreciated 
by those skilled in the art that the porous microspheres 
of the present invention containing pore incorporated 
drugs for release to target cells or tissues, therefore, 
may be administered alone or in admixture with appro 
priate pharmaceutical diluents, carriers, excipients or 
adjuvants suitably selected with respect to the intended 
route of administration and conventional pharmaceuti 
cal practices. For example, for parenteral injection, 
dosage unit forms may be utilized to accomplish intra 
venous, intramuscular or subcutaneous administration, 
and for such parenteral administration, suitable sterile 
aqueous or non-aqueous solutions or suspensions, op 
tionally containing appropriate solutes to effectuate 
isotonicity, will be employed. Likewise for inhalation 
dosage unit forms, for administration through the 
mucus membranes of the nose and throat or bronchio 
pulmonary tissues, suitable aerosol or spray inhalation 
compositions and devices will be utilized. 
Consistent with other preferred embodiments of the 
present invention, the porous microspheric drug deliv 
ery systems of the invention may be additionally coated 
or modi?ed to advantageously in?uence the targeting 
of the release of the incorporated drug therein to prese 
lected target cells, tissues or organs. For example, the 
drug delivery microspheres may be coated with various 
agents, e.g., proteins, surfactants, antibodies or receptor 
site speci?c drugs which may be the same or different 
from those incorporated in the porous microsphere 
whereby the release of the incorporated drug is concen 
trated at the targeted system. 
The preparative methods of the present invention are 
generally depicted in FIGS. 4A and 4B. 
In accordance with the methods for making the po 
rous microspheres of the invention, the desired polymer 
4,818,542 
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or copolymer and the drug(s) or other agent(s) are 
dissolved separately in a suitable solvent. The polymer 
and drug solutions are mixed together in the appropri 
ate manner to provide a polymer concentration ranging 
between about 2.5 to 18% w/w and a drugzpolymer 
ratio ranging between about 1:1 to 1:10. The tempera 
ture of the resultant solution is controlled between 
about 30'-45° C. The drug-polymer solution compris 
ing the dispersed phase is dispersed into the continuous 
phase containing an appropriate surface active agent at 
a thermostatically controlled temperature generally in 
the range of l0°-20° C. The foregoing is accomplished 
by forcing the dispersed phase under pressure through a 
?ne ori?ce nozzle. The continuous phase which is 10-20 
times by weight of the dispersed phase is then agitated 
by a dispersator. Following the introduction of the 
dispersed phase, one of two recovery methods (see 
FIG. 4) is utilized to stabilize and recover the drug 
loaded microspheres for final processing. 
More speci?cally, consistent with the freeze-dry 
method of the invention, following dispersion, the tem 
perature is maintained at l0°-20° C., preferably 15‘ C., 
for two minutes then increased to 45°—55° C., preferably 
50" C., over a three minute period. Vigorous agitation 
of the mixture is continued during this period. When the 
temperature reaches 50“ C., either a refrigerant solution 
is circulated through the jacket from the bath or the 
container is immersed in dry ice-methanol and cooled to 
a temperature which will freeze the drug-polymer-sol 
vent phase and not the continuous phase. The suspen 
sion or emulsion (solid dispersion phase in liquid contin 
uous phase) is quickly transferred to precooled vials 
(—40° to —60° C.) and cooled to —40° to —60° C. in a 
freeze dryer, freezer or dry ice-acetone bath. The sol 
vent in the suspended droplets (microspheres) and the 
continuous phase solvent are removed by freeze drying. 
Upon completion of the freeze dry cycle the micro 
spheres are washed with a suitable solvent, ?ltered and 
air dried. 
In the dilution-precipitation method of the invention, 
following dispersion, the temperature is maintained at 
l0°-20' C., preferably 15' C., for two minutes, then 
increased to 45°—55° C., preferably 50° C., over a three 
minute period. The dispersion is then transferred to a 
vessel containing a diluent solvent at room temperature 
as depicted in FIG. 4. Agitation is continued for 30 
minutes using a vibromixer. During the process the 
dispersed phase solvent is removed from the drug~ 
polymer-solvent emulsion droplets by extraction caus 
ing solidi?cation of the droplets. The solid spheres are 
then removed by ?ltration, washed with a suitable sol 
vent and air dried. 
Solvents for the dispersed phase and the continuous 
phase will of course differ in order to attain phase sepa~ 
ration and, are therefore, selected based upon the sol 
vent requirements for each phase. More particularly, 
the solvent for the dispersed phase should dissolve the 
polymer and the incorporated agent and remain in the 
emulsi?ed droplets with the drug and polymer in the 
continuous phase until leached out by a diluent solvent 
or removed by vaporization or evaporation. In this way 
pores are formed in the drug-polymer matrix. In the 
case of PGA polymer into which water soluble markers 
or agents are incorporated, hexa?uoroacetone sesquihy 
drate (EPA) is an appropriate solvent. Other solvents 
which can be used, depending upon characteristics of 
polymer and incorporated agents, include water, hexa 
fluoroisopropanol (HFIP), methylene chloride, tetrahy 
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drofuran, hexane, benzene. Solvents for the continuous 
phase should not dissolve the polymer and should emul 
sify the dispersed phase. Solvents include benzene, di 
oxane, acetone, methylene chloride, chloroform, car 
bon tetrachloride, toluene, ethyl alcohol, acetonitrile, 
p-xylene, tetrahydrofuran and mixtures of these sol 
vents. ' 
A diluent (non-solvent) phase can also be employed 
to dilute the continuous phase following dispersion of 
the polymeragent solution. The diluent should be misci 
ble with the continuous phase and dispersed phase sol 
vents ‘but not dissolve the polymer or incorporated 
agent. Examples of solvents include 1,4.dioxane, cyclo 
hexanone, acetone, ethanol, acetonitrile, dimethylform 
amide, tetrahydrofuran and cyclohexanol. 
The concentration of polymer in the dispersed phase 
directly influences the porosity or “void” space in the 
?nal microsphere product as well as the shape of the 
microsphere. A concentration of 2.5% to 10% w/w 
polymer yields dimensionally suitable spherical parti 
cles. With respect to the concentration of the pore in 
corporated agent, up to 50% by weight of the polymer 
has been achieved with consistent results. 
In accordance with another preferred embodiment of 
the present invention, hydrophilic colloids are em 
ployed to improve the yield and prevent phase inver 
sion in the continuous and diluent phases. Substances 
which can be utilized in concentrations ranging be 
tween about 0.5 to 5% include anionic surfactants such 
as sorbitan, gelatin and gelatin derivatives, polyvinyl 
alcohol, polystyrene sulfonate, hydroxyethylcellulose, 
hydroxypropylcellulose and related colloids with suit 
able hydrophilicity. . 
It has been determined that certain processing param 
eters influence the recovery methods as well as the 
resultant microspheres of the present invention. Identi 
?able parameters include the concentration of polymer 
in the dispersed phase, the temperature of the dispersed 
phase at the time of dispersion, the concentration of 
surfactants in the dispersed phase as well as the ratio of 
incorporated agent to polymer in the dispersed phase. It 
will be appreciated that the concentrations, tempera 
tures and ratios referred to hereinabove and in the Ex 
amples set forth operable ranges and that other numeri 
cal expressions may apply as different solvents, poly 
mers, incorporated agents, etc. are selected. 
The shape and surface appearance of microspheres 
prepared in accordance with the recovery methods of 
the invention were assessed by Scanning Electron Mi 
croscopy (SEM), FIGS. 5-7 as well as by optical mi 
crography. 
Typical release pro?les are also shown in FIGS. 7-9 
. The very water soluble FD&C dye Blue #1 releases 
within l~3 days depending upon the concentration of 
dye (i.e., marker). In all instances release is completed 
before discernible degradation or erosion of the matrix 
occurs. FIGS. 10 and 11 show SEM micrographs of the 
spheres following 72 hours and 120 hours, respectively, 
in the dissolution media. The spheres were essentially 
intact indicating minimal erosion. The release of a less 
soluble compound, prednisolone acetate is shown in 
FIG. 9. Essentially 90% of the drug was released after 
7 days and degradation of the matrix was very evident 
after 7 days as shown by the fragmentation in FIG. 12. 
The following non-limiting Examples are afforded in 
order that those skilled in the art may more readily 
understand the present invention and speci?c preferred 
embodiments thereof with respect to the methods and 
4,818,542 
compositions in accordance with the foregoing descrip 
tion. 
EXAMPLE 1 
FD&C Blue #1 - PGA microspheres (freeze dry 
recovery) 
1. 0.1 g of FD&C Blue #1 was dissolved in 9.9 g of 
HFA to make a 1% (w/w) solution. 
2. 1.0 g of PGA was dissolved in 9.0 g of HFA to make 
a 10% (w/w) solution. 
3. Equal weights of the above are mixed together to 
form the dispersed phase. The resultant spheres from 
this combination are very porous having 94.5% 
“void” space and a dye-polymer ratio of 1:10. In this 
example 2.0 g of each solution were mixed together 
and maintained at 37° C. The spherical microporous 
polymeric network has a degree of porosity of be 
tween about 80 to 98 percent as determined by rela 
tive void space in relation to the starting concentra 
tion of the polymer. 
DisErsed Phase Concentrations: 
DYE POLYMER SOLVENT 
20 mg 200 mg 3780 mg 
0.5% 5.0% 94.5% 
4. ‘The continuous phase constituted 160 g of CC14 con 
taining 0.1% sorbitan sesquioleate (SO-15) which was 
maintained at 15° C. in a 500 ml jacketed vessel. A 
dispersator was located at the center of the vessel for 
mixing. 
5. The dye-polymer-solvent solution was then dispersed 
via pressure through a ?ne ori?ce into the continuous 
_ phase which was agitated vigorously with the disper 
sator. The temperature was maintained at 15° C. and 
the mixing continued for 2 minutes. The temperature 
was then increased to 50° C. over a 3 minute period 
by either circulating 70° C. water through the jacket 
(or immersing the vessel in a 70° C. water bath). 
6. When the temperature reached 50°, a refrigerant 
solution at —22° C. was circulated through the jacket 
to freeze the dispersed phase and not the continuous 
phase (f.p. of CCl4= —22.6°). 
7. The above suspension was quickly transferred to 
pre-cooled (ca --45° C.) 50 m1 vials and cooled to 
-—40° to ~50‘ on the shelves in a freeze dryer which 
had been precooled to —50° C. 
8. The suspension was maintained at —50° for 1 hour. 
Vacuum was applied and the shelves heated to —- 10° 
C. and maintained at this temperature for 24 hours to 
remove the CC14. The temperature of shelves was 
increased to 20° C. for 24 hours to remove the HFA. 
The temperature of the shelves was increased to 35° 
and maintained for 2 hours to ensure removal of all 
solvent. 
9. The vials containing the spheres were removed from 
the chamber and stoppered pending washing and 
evaluation. 
EXAMPLE 2 
Prednisolone acetate-PGA microspheres (freeze dry 
recovery) 
0.1 g of predonisolone acetate was dissolved in 9.9 g of 
HFA to make a 1% w/w solution. 
1.0 g of PGA was dissolved in 9.0 g of HFA to make a 
10% w/w solution. 
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2.0 g of each solution were mixed together and main 
tained at 37° C. 
DisErsed Phase Concentrations: 
DRUG POLYMER SOLVENT 
20 mg 200 mg 3780 mg 
0.5% 5.0% 94.5% 
4-9. Steps four through nine were the same as in Exam 
ple 1. 
Spheres obtained by the freeze dry were washed 
twice with 125 ml volumes of acetone and collected on 
0.8, l0, 8!. 50 pm ?lters. The spheres obtained by the 
precipitation method were washed with acetone in the 
size ranges previously obtained by ?ltration and col 
lected on 0.8, 10, 8t 50 um ?lters. Washing removes 
approximately 8.5% of the dye or drug from the sphere. 
EXAMPLE 3 
Characterization of Microporous Microspheres and 
Release of Model Compounds ' 
SEM Photomicrographs of Examples, 1, and 2 are 
shown in FIGS. 5-7 at 10-fold differences in magni?ca 
tion. The porous nature is evident from the topography 
of the magni?ed surfaces of both methods of prepara 
tion. 
In-vitro release from the microspheres was deter 
mined in 0.1M phosphate buffer (pH 7.4). The spheres 
were quantitatively transferred to a 15 ml cuvette tube 
with a screw cap and the buffer added. The tubes were 
placed on a rocker-type shaker in an oven at 37° C. The 
tubes were centrifuged at various times and solution 
samples were removed for spectrophotometric analysis 
at 630 nm for FD&C Blue #1 and at 245 nm for prednis 
olone acetate. Release pro?les are shown in FIGS. 7_9 
for Examples 1 and 2 along with the pro?les of other 
compositions. The release of water soluble dye was 
essentially complete in 2 to 3 days with spheres pre 
pared by the precipitation and freeze dry methods while 
the less-soluble prednisolone acetate releases much 
more slowly, 90% in 7 days. 
In experiments at a ?xed level of dye, i.e., 4% (by 
weight of polymer) and variable polymer concentration 
in the dispersed phase (2.5%, 5% & 10%), the release 
rate was reduced in relation to the polymer concentra 
tion (FIG. 13). The “void” space or the porosity is 
controlled by the polymer (or solvent) concentration of 
the dispersed phase. 
EXAMPLE 4 
FD&C Blue #1 - PGL microspheres 
(Dilution-Precipitation Recovery) 
1. 0.1 g of FD&C Blue #1 was dissolved in 9.9 g of 
HFA to make a 1% (w/w) solution. 
2. 0.5 g of polygalactin 910 (VicrylR) was dissolved in 
4.5 g of HFA to make a 10% (w/w) solution. 
3. Equal weights of the above were mixed together to 
form the dispersed phase and maintained at 37° C. 
Dispersed Phase Concentrations: 
DYE POLYMER SOLVENT 
20 mg 200 mg 3780 mg 
0.5% 5.0% 94.5% 




